Grünenthal Press Releases 2014

Grünenthal USA “Unsung Hero Award”

US Patient Ambassador – Susan Stephenson & Paul Gileno recipient of the “Unsung Hero Award” for 2014

Grünenthal USA recently held its 2nd annual networking event at the Friars Club in NYC and awarded the first–ever “Unsung Hero Award” to Paul Gileno, founder of the US Pain Foundation.

The “Unsung Hero Award” is given to an individual who has made significant contributions to advance the social awareness of pain and suffering for those living with chronic pain. Nominations for the award were solicited from attendees of last year’s event. The criteria for the award are: relevance, impact, innovation, scope of outreach and commitment related to pain awareness, improvements and advancements in pain policies.

Paul overwhelmingly fit the criteria as a chronic pain patient himself and founder of the US Pain Foundation which serves to connect and inform patients, and advocate for the pain community. The US Pain Foundation has attracted more than 40,000 members across the USA since 2011and is quickly growing. For further information please visit www.uspainfoundation.org.

Please join us in congratulating Paul Gileno as recipient of the “Unsung Hero Award” for 2014.

About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grünenthal′s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved preliminary revenues of € 973 mn.

More information: www.grunenthal.com

Back